Alexion Pharmaceuticals PT Raised to $139.00 (ALXN)
Stock analysts at Goldman Sachs Group Inc. lifted their target price on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $122.00 to $139.00 in a report issued on Wednesday, Analyst Ratings Network.com reports. Goldman Sachs Group Inc.’s price objective suggests a potential upside of 19.90% from the company’s current price.
A number of other analysts have also recently weighed in on ALXN. Analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note to investors on Thursday, August 15th. They now have a $115.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $88.00 to $97.00 in a research note to investors on Friday, July 26th. They now have a “hold” rating on the stock.
One analyst has rated the stock with a sell rating, six have given a hold rating and eleven have given a buy rating to the company. Alexion Pharmaceuticals has an average rating of “Buy” and an average price target of $118.18.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 1.48% on Wednesday, hitting $115.932. 837,161 shares of the company’s stock traded hands. Alexion Pharmaceuticals has a one year low of $81.82 and a one year high of $125.65. The stock has a 50-day moving average of $111.1 and a 200-day moving average of $100.9. The company has a market cap of $22.671 billion and a price-to-earnings ratio of 65.13.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.05. The company had revenue of $370.10 million for the quarter, compared to the consensus estimate of $364.80 million. During the same quarter in the previous year, the company posted $0.47 earnings per share. The company’s revenue for the quarter was up 34.7% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $3.04 earnings per share for the current fiscal year.
In other Alexion Pharmaceuticals news, Director Joseph A. Madri unloaded 30,000 shares of Alexion Pharmaceuticals stock on the open market in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $115.00, for a total transaction of $3,450,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.